11:42:24 EDT Wed 28 Jun 2017
Enter Symbol
or Name
USA
CA



Z:SNY - SANOFI - http://www.sanofi-aventis.com11:42:24 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SNY - Z0.249.27 · 49.281.449.27-0.020.0239.810,1591,29049.36  49.47  49.2450.24  36.8111:27:21Jun 2715 min RT 2¢

Recent Trades - Last 10 of 1290
Time ETExPriceChangeVolume
11:27:21Z49.27-0.0218
11:27:19Z49.27-0.02100
11:27:19Z49.27-0.02100
11:27:17Z49.28-0.0125
11:27:17Z49.28-0.01100
11:27:02Z49.29 100
11:26:59Z49.29 100
11:26:57Z49.29010.000132
11:26:25Z49.300.01100
11:26:20Z49.300.01100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2017-06-27 08:00U:SNYNews ReleaseAmerican Academy of Family Physicians Foundation Launches Highlight on VACCINATIONS 4 TEENS to Help Address Teen Under-Vaccination
2017-06-27 01:00U:SNYNews ReleaseRegeneron and Sanofi Announce Approval of Kevzara ® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
2017-06-11 11:01U:SNYNews ReleaseSanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent ® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
2017-06-11 11:00U:SNYNews ReleaseRegeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent ® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
2017-06-10 13:01U:SNYNews ReleaseIn Senior Adults Treated with Basal Insulin, Switching to Sanofi's Toujeo ® Halved Hypoglycemia Risk
2017-06-10 13:01U:SNYNews ReleaseNew Analysis Shows Sanofi's Soliqua ® 100/33 Lowered HbA1c by More Than 2 Percent in Patients with Screening Levels Greater than 9 Percent
2017-06-04 10:00U:SNYNews ReleaseSanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
2017-06-04 10:00U:SNYNews ReleaseRegeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting